OR WAIT null SECS
© 2023 MJH Life Sciences and Consultant Live. All rights reserved.
May 31, 2023
Patients treated with NAL ER demonstrated a 75.1% decrease in daytime cough frequency and a 76.1% decrease in 24-hour cough frequency compared with placebo.
May 16, 2023
The phase 3 clinical trials evaluating ziritaxestat for treating idiopathic pulmonary fibrosis showed no improvement in clinical outcomes leading to the termination of the trials due to lack of efficacy.
April 03, 2023
In the latest Lungcast, a pair of experts considered the marriage of low-dose CT scanning and machine learning to optimize lung disease interception.
March 27, 2023
As the US tries to move on from the pandemic, patients with long COVID-19 are fighting to regain normalcy while clinicians improve care plans and researchers search for answers.
February 17, 2023
According to the systmatic review, motavizumab, nirsevimab, and palivizumab, are associated with significant reductions in RSV-related infections and hospitalizations without a significant increase in adverse events.